Boulding Mark Elliott

Avg. Two Year Performance

No purchase track record

24% Avg. Sale Return

11% Compound

	1 Mo	3 Mo	6 Mo	1 Yr	2 Yr
Average Purchase Return	--	--	--	--	--
Purchase Success Rate	--	--	--	--	--
Average Sale Return	4%	9%	14%	22%	24%
Sale Success Rate	2 of 11	3 of 11	2 of 11	2 of 11	3 of 11

Ptc Therapeutics, Inc.

Drugs » Biotechnology

Exec. VP and CLO:

Holdings: 92.39K shares

Sentiment

Avg. Two Year Performance

No purchase track record

No sale track record

Last Three Months:

0 Net Amount

Buy:	0	--
Sell:	0	--